Saltar al contenido
Merck

SML0492

Sigma-Aldrich

Zanamivir

≥98% (HPLC)

Sinónimos:

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C12H20N4O7
Número de CAS:
Peso molecular:
332.31
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +30 to +40°, c = 1 in H2O

color

white to beige

solubility

H2O: 10 mg/mL, clear

storage temp.

room temp

SMILES string

CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

InChI

1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

InChI key

ARAIBEBZBOPLMB-UFGQHTETSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Zanamivir has been used:
  • as a neuraminidase inhibitor to study its effects on influenza A virus (IAV) like particles
  • as a neuraminidase inhibitor to study its effects on lipopolysaccharide (LPS)-mediated pathology in sepsis
  • as an antiviral to study its effects on influenza B virus by plaque reduction assay

Biochem/physiol Actions

Zanamivir exhibits therapeutic effects against influenza caused by influenza virus A and B.
Zanamivir is an influenza viral neuraminidase inhibitor.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Emi Takashita et al.
Antimicrobial agents and chemotherapy, 59(5), 2607-2617 (2015-02-19)
Between September 2013 and July 2014, 2,482 influenza 2009 pandemic A(H1N1) [A(H1N1)pdm09] viruses were screened in Japan for the H275Y substitution in their neuraminidase (NA) protein, which confers cross-resistance to oseltamivir and peramivir. We found that a large cluster of
Benjamin O Fulton et al.
Journal of virology, 89(23), 12226-12231 (2015-09-25)
Influenza B virus is a human pathogen responsible for significant health and economic burden. Research into this pathogen has been limited by the lack of reporter viruses. Here we describe the development of both a replication-competent fluorescent influenza B reporter
Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Javier Magano
Chemical reviews, 109(9), 4398-4438 (2009-06-23)
Mila B Ortigoza et al.
mBio, 15(2), e0220323-e0220323 (2024-01-11)
The ongoing transmission of influenza A viruses (IAV) for the past century continues to be a burden to humans. IAV binds terminal sialic acids (SA) of sugar molecules present within the upper respiratory tract (URT) in order to successfully infect
Carl J Heneghan et al.
BMJ (Clinical research ed.), 348, g2547-g2547 (2014-05-09)
To describe the potential benefits and harms of zanamivir. Systematic review of clinical study reports of randomised placebo controlled trials and regulatory information Clinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers. Randomised placebo controlled trials

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico